NO20092314L - Benzamidderivater som EP4 receptoragonister - Google Patents

Benzamidderivater som EP4 receptoragonister

Info

Publication number
NO20092314L
NO20092314L NO20092314A NO20092314A NO20092314L NO 20092314 L NO20092314 L NO 20092314L NO 20092314 A NO20092314 A NO 20092314A NO 20092314 A NO20092314 A NO 20092314A NO 20092314 L NO20092314 L NO 20092314L
Authority
NO
Norway
Prior art keywords
receptor agonists
benzamide derivatives
compounds
benzamide
derivatives
Prior art date
Application number
NO20092314A
Other languages
English (en)
Norwegian (no)
Inventor
Christopher Norbert Johnson
Steven James Stanway
Alessandra Gaiba
Mark Patrick Healy
Susan Roomans
Martin Edward Swarbrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625098A external-priority patent/GB0625098D0/en
Priority claimed from GB0715145A external-priority patent/GB0715145D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20092314L publication Critical patent/NO20092314L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
NO20092314A 2006-12-15 2009-06-16 Benzamidderivater som EP4 receptoragonister NO20092314L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625098A GB0625098D0 (en) 2006-12-15 2006-12-15 Novel compounds
GB0715145A GB0715145D0 (en) 2007-08-03 2007-08-03 Novel compounds
PCT/EP2007/063796 WO2008071736A1 (en) 2006-12-15 2007-12-12 Benzamide derivatives as ep4 receptor agonists

Publications (1)

Publication Number Publication Date
NO20092314L true NO20092314L (no) 2009-08-31

Family

ID=39149241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092314A NO20092314L (no) 2006-12-15 2009-06-16 Benzamidderivater som EP4 receptoragonister

Country Status (21)

Country Link
US (3) US8314147B2 (pt)
EP (1) EP2101751A1 (pt)
JP (1) JP5069752B2 (pt)
KR (1) KR20090089868A (pt)
AR (1) AR064361A1 (pt)
AU (1) AU2007331471C1 (pt)
BR (1) BRPI0720254A2 (pt)
CA (1) CA2672631A1 (pt)
CL (1) CL2007003640A1 (pt)
CR (1) CR10849A (pt)
DO (1) DOP2009000124A (pt)
EA (1) EA015931B1 (pt)
IL (1) IL198931A0 (pt)
MA (1) MA30991B1 (pt)
MX (1) MX2009006474A (pt)
NO (1) NO20092314L (pt)
NZ (1) NZ577109A (pt)
PE (1) PE20081579A1 (pt)
SG (1) SG177203A1 (pt)
TW (1) TW200848014A (pt)
WO (1) WO2008071736A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
ES2471919T3 (es) * 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
SI2565191T1 (sl) * 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
GB0810313D0 (en) * 2008-06-05 2008-07-09 Glaxo Group Ltd Novel compounds
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
GB0810617D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
US8778939B2 (en) * 2009-09-29 2014-07-15 Glaxo Group Limited Compounds
CN104292154A (zh) * 2009-09-29 2015-01-21 葛兰素集团有限公司 新化合物
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
MX2013001227A (es) * 2010-07-30 2013-04-24 Allergan Inc Compuestos y metodos para reparacion de piel.
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
PH12013500467A1 (en) 2010-09-21 2013-04-29 Eisai R&D Man Co Ltd Pharmaceutical composition
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
EP2814527A1 (en) * 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PT3113773T (pt) * 2014-03-06 2019-11-12 Aratana Therapeutics Inc Formas cristalinas do grapiprant
US10407376B2 (en) 2015-01-16 2019-09-10 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method to prepare phenolics from biomass
EP3184505A1 (en) 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Method for preparing phenolics using a catalyst
CN113905732A (zh) * 2019-04-09 2022-01-07 纽罗比特科学有限公司 用于预防或治疗脊髓损伤或椎管狭窄的药物组合物
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN111454150B (zh) * 2019-12-25 2023-03-28 南京工业大学 一种(s)-2-芳基丙酸酯类化合物的合成方法
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003207900A1 (en) 2002-03-18 2003-09-29 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
PL373246A1 (en) 2002-04-12 2005-08-22 Pfizer Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
JP4754820B2 (ja) 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
WO2004037813A1 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CN1735597A (zh) 2003-01-10 2006-02-15 霍夫曼-拉罗奇有限公司 作为前列腺素激动剂的2－哌啶酮衍生物
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
RS20060143A (sr) 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
CN1950334A (zh) 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
JP4054368B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 置換メチルアリール又はヘテロアリールアミド化合物
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten

Also Published As

Publication number Publication date
BRPI0720254A2 (pt) 2014-01-07
EA015931B1 (ru) 2011-12-30
NZ577109A (en) 2011-12-22
JP5069752B2 (ja) 2012-11-07
AR064361A1 (es) 2009-04-01
CL2007003640A1 (es) 2008-07-11
TW200848014A (en) 2008-12-16
MA30991B1 (fr) 2009-12-01
DOP2009000124A (es) 2010-03-31
CA2672631A1 (en) 2008-06-19
US20130261185A1 (en) 2013-10-03
EP2101751A1 (en) 2009-09-23
AU2007331471B2 (en) 2013-01-10
CR10849A (es) 2009-08-12
WO2008071736A1 (en) 2008-06-19
KR20090089868A (ko) 2009-08-24
MX2009006474A (es) 2009-06-26
US20080167377A1 (en) 2008-07-10
EA200970585A1 (ru) 2009-10-30
IL198931A0 (en) 2010-02-17
SG177203A1 (en) 2012-01-30
JP2010513242A (ja) 2010-04-30
AU2007331471A1 (en) 2008-06-19
AU2007331471C1 (en) 2013-07-25
US8314147B2 (en) 2012-11-20
US20100022650A1 (en) 2010-01-28
PE20081579A1 (es) 2009-01-01

Similar Documents

Publication Publication Date Title
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
NO20083434L (no) Benzamid- og heteroarenderivater
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20074703L (no) Antibakterielle piperidinderivater
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
NO20073332L (no) Pyridinforbindelser for behandling av prostaglandinmedierte sykdommer
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20090628L (no) Pyridizinon derivativater
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
NO20083448L (no) Benzo(f)isoindol-2-ylfenyleddiksyrederivater som EP4 receptoragonister
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
WO2008006795A3 (en) Indole compounds
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
NO20081217L (no) Nye benzotiazolonderivater
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
NO20064705L (no) Nye farmasoytiske preparater omfattende agonister av tyroidreseptoren

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application